PSTV

Plus Therapeutics, Inc. [PSTV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PSTV Stock Summary

Top 10 Correlated ETFs

PSTV

Top 10 Correlated Stocks

PSTV

In the News

PSTV Financial details

Company Rating
-
Market Cap
7.95M
Income
-13.32M
Revenue
4.91M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
-0.41
Forward P/E
-
PEG
0.07
P/S
4.22
P/B
2.39
P/C
-
P/FCF
-0.66
Quick Ratio
1.05
Current Ratio
1.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.5
EPS next Y
-
EPS next Q
-
EPS this Y
-64.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-50.18%
Revenue last 5Y
-6.83%
Revenue Q/Q
5.89%
EPS Q/Q
-16%
-
-
-
-
SMA20
-20%
SMA50
-33.33%
SMA100
-42.86%
Inst Own
-
Inst Trans
-
ROA
-115%
ROE
-424%
ROC
-5.49%
Gross Margin
100%
Oper. Margin
-723%
Profit Margin
-734%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.97-5.1
52W High
-
52W Low
-
RSI
36
Rel Volume
6.57
Avg Volume
29.79K
Volume
195.79K
Perf Week
-3.14%
Perf Month
-31.73%
Perf Quarter
-45.43%
Perf Half Y
-74.13%
-
-
-
-
Beta
0.558
-
-
Volatility
0.17%, 0.6%
Prev Close
-5.13%
Price
3.7
Change
-8.87%

Something similar

Top by Market Cap
VTSAX
AMZ.DE
GOOG
M&M.NS
FB2A.DE
Top Correlated ETFs
3097.HK
3175.HK
USO
UCO
DBO
Top Correlated Stocks
0R23.L
8196.HK
0837.HK
HAL
SLB
Similar Market Cap
ARTH
QCCO
ALDA
OWPC
FOX.L

Company Profile

Healthcare Biotechnology
  • Volume Average 29.79K
  • Market Capitalization 7.95M
  • Employee 20
  • CEO Dr. Marc H. Hedrick M.B.A., M.D.
  • Headquarters Austin,TX,US
  • IPO Date 2001-07-11
  • Website https://www.plustherapeutics.com

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.